Cadila Healthcare arm gets USFDA nod for Haloperidol Decanoate injection to treat schizophrenia
Haloperidol is used in the treatment of schizophrenia and for the control of tics and vocal utterances of Tourette syndrome, Cadila Healthcare said.
NEW DELHI: Drug firm Cadila Healthcare on Thursday said it has received approval from the USFDA for Haloperidol Decanoate injection used in the treatment of schizophrenia. The product will be manufactured at Liva Pharma's manufacturing facility at Vadodara, Cadila Healthcare said in a BSE filing.
Haloperidol is used in the treatment of schizophrenia and for the control of tics and vocal utterances of Tourette syndrome.
Read Also: Cadila Healthcare largest API manufacturing site clears USFDA inspection
"Liva Pharmaceuticals Limited, a wholly-owned subsidiary company of Cadila Healthcare Limited, has received the approval from the USFDA for Haloperidol Decanoate Injection, 50 mg (base)/mL and 100 mg (base)/mL, single-dose vials, 250 mg (base)/5 mL (50 mg (base)/mL) and 500 mg (base)/5 mL (100 mg (base)/mL)
Read Also: Zydus Cadila gets USFDA nod for Colesevelam Hydrochloride tablets for lowering cholesterol
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd